Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.60 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.60 |
| ▸ | SREBF2 | Q12772 | 11/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279440 | 0.91 | SREBF2 (0.57) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL4283901 | 0.91 | SREBF2 (0.58) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL19733086 | 0.84 | SREBF2 (0.55) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL4288916 | 0.79 | SREBF2 (0.55) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL4286677 | 0.79 | SREBF2 (0.54) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL952531 | 0.79 | CDC7 (0.67) | CDC7DBF4CCNE1CDK2KDM4E | |
| SCHEMBL954260 | 0.79 | CDC7 (0.60) | CDC7DBF4CCNE1CDK2KDM4E | |
| SCHEMBL4279577 | 0.77 | SREBF2 (0.53) | CDC7DBF4SREBF2KDM4ELMNA | |
| SCHEMBL974859 | 0.76 | CDC7 (0.84) | CDC7DBF4CCNE1CDK2KDM4E | |
| SCHEMBL19733079 | 0.76 | SREBF2 (0.56) | CDC7DBF4SREBF2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | claimed |
| US-8778976-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2014-07-15 | — | — | US | claimed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | claimed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | claimed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | claimed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | claimed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | claimed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-08-04 | — | — | US | disclosed |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8207196-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2120580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | Baylor College Of Medicine (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008097835-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | CDC7 372/4885DBF4 1538/4885SREBF2 1767/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | CDC7 3065/4885DBF4 2035/4885SREBF2 17/4885 |
| US-20130012538-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | CDC7 3264/4885DBF4 1777/4885SREBF2 31/4885 |
| US-20130005768-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | CDC7 3264/4885DBF4 1777/4885SREBF2 31/4885 |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | CDC7 3264/4885DBF4 1777/4885SREBF2 31/4885 |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | CDC7 3264/4885DBF4 1777/4885SREBF2 31/4885 |
| US-20090131475-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | CDC7 3241/4885DBF4 1943/4885SREBF2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.